F Grases1, J Perelló, B Isern, R M Prieto. 1. Laboratory of Renal Lithiasis Research and Biomineralization, University Institute of Health Sciences Research (IUNICS), University of Balearic Islands, 07122 Palma de Mallorca, Spain. fgrases@uib.es
Abstract
BACKGROUND: Calcinosis cutis is a disorder caused by abnormal deposits of calcium phosphate in the skin and is observed in diverse disorders. Myo-inositol hexaphosphate (InsP(6)) is a diet-dependent molecule found in all mammalian fluids and tissues, which exhibits an extraordinary capacity as a crystallization inhibitor of calcium salts. OBJECTIVES: To establish the effects of topically administered InsP(6) cream on artificially provoked dystrophic calcifications in soft tissues. METHODS: Fourteen male Wistar rats were randomly assigned into two groups: control and treated groups. Rats were fed with an InsP(6)-free or phytate diet. Plaque formation was induced by subcutaneous injection of 0.1% KMnO(4) solution. From 4 days before plaque induction to the end of the experiment, control rats were treated topically with a standard cream, whereas treated rats were treated with the same cream with 2% InsP(6) or phytate (as sodium salt). Calcification of plaques was allowed to proceed for 10 days. InsP(6) in urine was determined. The plaques were excised and weighed. RESULTS: It was found that when InsP(6) was administered topically through a moisturizing cream (2% InsP(6)-rich), the plaque size and weight were notably and significantly reduced compared with the control group (1.6 +/- 1.1 mg InsP(6)-treated, 26.7 +/- 3.0 mg control). The InsP(6) urinary levels for animals treated with the InsP(6)-enriched cream were considerably and significantly higher than those found in animals treated topically with the cream without InsP(6) (16.96 +/- 4.32 mg L(-1) InsP(6)-treated, 0.06 +/- 0.03 mg L(-1) control). CONCLUSIONS: This demonstrates the important capacity of InsP(6) as a crystallization inhibitor and also demonstrates that it is possible to propose topical use as a new InsP(6) administration route.
BACKGROUND:Calcinosis cutis is a disorder caused by abnormal deposits of calcium phosphate in the skin and is observed in diverse disorders. Myo-inositol hexaphosphate (InsP(6)) is a diet-dependent molecule found in all mammalian fluids and tissues, which exhibits an extraordinary capacity as a crystallization inhibitor of calcium salts. OBJECTIVES: To establish the effects of topically administered InsP(6) cream on artificially provoked dystrophic calcifications in soft tissues. METHODS: Fourteen male Wistar rats were randomly assigned into two groups: control and treated groups. Rats were fed with an InsP(6)-free or phytate diet. Plaque formation was induced by subcutaneous injection of 0.1% KMnO(4) solution. From 4 days before plaque induction to the end of the experiment, control rats were treated topically with a standard cream, whereas treated rats were treated with the same cream with 2% InsP(6) or phytate (as sodium salt). Calcification of plaques was allowed to proceed for 10 days. InsP(6) in urine was determined. The plaques were excised and weighed. RESULTS: It was found that when InsP(6) was administered topically through a moisturizing cream (2% InsP(6)-rich), the plaque size and weight were notably and significantly reduced compared with the control group (1.6 +/- 1.1 mg InsP(6)-treated, 26.7 +/- 3.0 mg control). The InsP(6) urinary levels for animals treated with the InsP(6)-enriched cream were considerably and significantly higher than those found in animals treated topically with the cream without InsP(6) (16.96 +/- 4.32 mg L(-1) InsP(6)-treated, 0.06 +/- 0.03 mg L(-1) control). CONCLUSIONS: This demonstrates the important capacity of InsP(6) as a crystallization inhibitor and also demonstrates that it is possible to propose topical use as a new InsP(6) administration route.
Authors: Ali Murat Tatlı; Seyda Gunduz; Sema Sezgin Göksu; Deniz Arslan; Mukremin Uysal; Cumhur İbrahim Başsorgun; Hasan Şenol Coşkun Journal: Case Rep Oncol Med Date: 2013-07-15